Doxorubicin liposomal

多柔比星脂质体

Report date: 2026/05/16 20:00:17

Base Information

Drug NameDoxorubicin liposomal
Drug Alias NameLiposome encapsulated doxorubicinLyso-thermosensitive liposomal doxorubicinLiposomal DoxorubicinDox-SLPegylated liposomal doxorubicin +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA intercalatorsTopoisomerase II inhibitorsReactive oxygen species stimulants +[4] 
TargetsReactive oxygen speciesTopoisomerase IIDNA
Therapy Area/IndicationsLymphohistiocytosis, HemophagocyticFallopian Tube NeoplasmsSoft Tissue Neoplasms +[20] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesImunon Inc
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Jiao Tong University School of MedicineNational Health Research InstitutesCordgenics Llc +[7] 
Inactive CompaniesUniversity Of OxfordImunon IncAmri Burlington, Inc +[4] 
Active IndicationsLymphohistiocytosis, HemophagocyticFallopian Tube NeoplasmsSoft Tissue Neoplasms +[15] 
Inactive IndicationsPancreatic NeoplasmsLiver NeoplasmsBreast Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A